This site is intended for healthcare professionals
News

Phase III PANORAMA trial of Eylea shows positive results in diabetic retinopathy.- Regeneron Pharma

Read time: 1 mins
Published:10th Feb 2020
Regeneron Pharmaceuticals announced positive two-year results from the Phase III PANORAMA trial evaluating Eylea (aflibercept) Injection 2 mg (0.05 mL) in patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR). The two-year pre-specified exploratory data demonstrate that untreated moderately severe and severe NPDR can lead to vision-threatening events, which includes vision-threatening complications (VTCs; proliferative diabetic retinopathy or anterior segment neovascularization) and center-involved diabetic macular edema (CI-DME). Based on a Kaplan-Meier analysis, more than half (58%) of patients in the untreated sham arm developed a VTC or CI-DME within two years of entering the trial, while Eylea treatment was shown to reduce the likelihood of these vision-threatening events by at least 75%. The two-year results also showed a greater benefit for Eylea patients treated at regular intervals compared to patients who received Eylea treatment less frequently. Per the protocol, the group of trial patients who received Eylea every 8 weeks in the first year were switched to receive it when their doctor determined they needed it (called pro re nata, or PRN) in the second year (i.e., the 8-week/PRN group). The proportion of these patients with a >2-step improvement from baseline in Diabetic Retinopathy Severity Scale (DRSS) scores decreased in the second year (80% improvement at 52 weeks and 50% at 100 weeks). By comparison, in patients who continued to receive Eylea every 16 weeks (i.e., the 16-week group), the >2-step DRSS scores remained consistent (65% at 52 weeks vs. 62% at 100 weeks). In the second year, patients received an average of 1.8 injections in the 8-week/PRN group (out of a possible 6); a review of data from the independent reading center of investigator PRN decisions suggests that some of these patients may have been under-dosed based on the protocol rules of the trial. Patients in the 16-week group received 2.6 injections (out of a possible 3) in the second year. During the 2-year PANORAMA trial, adverse events were consistent with the known profile of Eylea. Serious ocular adverse events in the study eye occurred in 2% and 0% of the Eylea 8-week/PRN and 16-week groups, respectively, and 2% of patients in the sham group. Ocular inflammation occurred in 2% and 1% of patients in the Eylea treatment groups, respectively, and 1% of patients in the sham group. Anti-platelet trialists' collaboration (APTC)-defined arterial thromboembolic treatment emergent events occurred in 3% and 6% of patients in the Eylea treatment groups, respectively, and 5% of patients in the sham group. The data were presented for the first time at the Angiogenesis, Exudation, and Degeneration 2020 meeting.
Condition: Diabetic Retinopathy
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.